Valneva
Franck Grimaud was co-founder, President and CEO of Vivalis and co-led its merger with Intercell to create Valneva.
He has a long-standing and proven track record in corporate and business development as well as strategic management with more than 20 years in the biotech industry.
Prior to creating and successfully building Vivalis as a French public biotech company he was responsible for the creation of the Asian subsidiaries of Groupe Grimaud, a leader in animal genetic selection and currently Valneva´s largest shareholder.
This person is not in any offices
Valneva
2 followers
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.